Online inquiry

IVTScrip™ mRNA-Anti-CD37, K7153A(Cap 0, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ9871MR)

This product GTTS-WQ9871MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD37 gene. The antibody can be applied in Non-Hodgkin's lymphoma (NHL) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Chimeric
RefSeq NM_001040031.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 951
UniProt ID P11049
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD37, K7153A(Cap 0, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ9871MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2718MR IVTScrip™ mRNA-Anti-CD19&CD3E, AMG103(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA AMG103
GTTS-WQ14575MR IVTScrip™ mRNA-Anti-CD19, aCD1919(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA aCD1919
GTTS-WQ13815MR IVTScrip™ mRNA-Anti-S, REGN-10987(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA REGN-10987
GTTS-WQ2598MR IVTScrip™ mRNA-Anti-MPL, AMG 531(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AMG 531
GTTS-WQ7543MR IVTScrip™ mRNA-Anti-CLDN18, GC-182(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA GC-182
GTTS-WQ6394MR IVTScrip™ mRNA-Anti-Factor IX substitute, CSL654(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CSL654
GTTS-WQ3567MR IVTScrip™ mRNA-Anti-LYPD3, BAY 1112623(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA BAY 1112623
GTTS-WQ152MR IVTScrip™ mRNA-Anti-CA9, 124I_WX-G250(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA 124I_WX-G250
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW